{"id":"standard-dose-rifampicin","safety":{"commonSideEffects":[{"rate":"null","effect":"Hepatotoxicity"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Flu-like symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition prevents the transcription of essential bacterial genes, ultimately leading to the death of the bacteria. Rifampicin is a broad-spectrum antibiotic that is effective against a wide range of bacteria, including Mycobacterium tuberculosis.","oneSentence":"Rifampicin inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:16.333Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis"},{"name":"Prophylaxis of Mycobacterium tuberculosis infection"}]},"trialDetails":[{"nctId":"NCT04930744","phase":"PHASE2","title":"Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2021-08-26","conditions":"Tuberculosis, Pulmonary Tuberculosis, HIV Coinfection","enrollment":112},{"nctId":"NCT06253715","phase":"PHASE3","title":"Shortened Regimen for Drug-susceptible TB in Children","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-01-15","conditions":"Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node","enrollment":860},{"nctId":"NCT06192160","phase":"PHASE2","title":"Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-11","conditions":"Pulmonary Tuberculosis","enrollment":315},{"nctId":"NCT07467252","phase":"PHASE2","title":"AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT","status":"NOT_YET_RECRUITING","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2026-09","conditions":"Pulmonary Tuberculosis","enrollment":200},{"nctId":"NCT07429331","phase":"PHASE1","title":"Drug Interaction and Food Effect Study of CS0159","status":"NOT_YET_RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2026-03","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT05556746","phase":"PHASE2","title":"Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-11-24","conditions":"Tuberculosis, Pulmonary, HIV","enrollment":94},{"nctId":"NCT06153069","phase":"PHASE4","title":"Asymptomatic TB With Innovative Modified Short-course Regimens","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-11-21","conditions":"Tuberculosis","enrollment":426},{"nctId":"NCT06498414","phase":"PHASE2, PHASE3","title":"Shorter and Safer Treatment Regimens for Latent TB","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-06-10","conditions":"Tuberculosis Infection, Latent","enrollment":1800},{"nctId":"NCT07069582","phase":"PHASE1","title":"Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-04-01","conditions":"Tuberculosis Infection, Healthy Volunteer, Breastfeeding","enrollment":60},{"nctId":"NCT06318416","phase":"PHASE1","title":"Precision Rifampin Trial for Personalized Dosing","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2025-10-01","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT07303699","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2026-01-03","conditions":"Pulmonary Tuberculosis (TB)","enrollment":80},{"nctId":"NCT06590428","phase":"NA","title":"Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis","status":"RECRUITING","sponsor":"Albert Einstein College of Medicine","startDate":"2026-03","conditions":"Rifampin-resistant Tuberculosis, Drug-resistant Tuberculosis","enrollment":280},{"nctId":"NCT06057519","phase":"PHASE3","title":"Pragmatic Optimized Rifampicin Trial","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2024-01-16","conditions":"Tuberculosis, Pulmonary","enrollment":164},{"nctId":"NCT04951986","phase":"PHASE3","title":"Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cape Town","startDate":"2021-08-11","conditions":"Disseminated Tuberculosis, HIV","enrollment":732},{"nctId":"NCT04738812","phase":"PHASE3","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-21","conditions":"Tuberculosis, HIV-1-infection, Immuno-Deficiency","enrollment":1330},{"nctId":"NCT05383742","phase":"PHASE2","title":"Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Tuberculous Meningitis","enrollment":330},{"nctId":"NCT05069688","phase":"PHASE1","title":"Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-07-07","conditions":"Pediatric HIV Infection, Tuberculosis Infection","enrollment":20},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT05807399","phase":"PHASE2","title":"PanACEA - STEP2C -01","status":"RECRUITING","sponsor":"Michael Hoelscher","startDate":"2023-04-14","conditions":"Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis","enrollment":390},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT04734652","phase":"PHASE2","title":"INSTI's For The Management of HIV-associated TB","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-02-18","conditions":"HIV/AIDS, Tuberculosis, Pulmonary","enrollment":122},{"nctId":"NCT06199921","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2024-01-03","conditions":"Pulmonary Tuberculosis, Tuberculosis, Koch's Disease","enrollment":440},{"nctId":"NCT06497465","phase":"PHASE3","title":"Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-09-18","conditions":"Tuberculosis, HIV","enrollment":150},{"nctId":"NCT02563327","phase":"PHASE3","title":"Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-05-30","conditions":"Tuberculosis","enrollment":53},{"nctId":"NCT03915366","phase":"PHASE2, PHASE3","title":"Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia","status":"COMPLETED","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2020-03-01","conditions":"Pneumonia, HIV/AIDS, Tuberculosis","enrollment":563},{"nctId":"NCT05473520","phase":"PHASE3","title":"Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2023-05-24","conditions":"Tuberculosis, Acute Coronary Syndrome, Pulmonary Hypertension (Diagnosis)","enrollment":150},{"nctId":"NCT06446245","phase":"PHASE2","title":"Adjunctive Doxycycline for Central Nervous System Tuberculosis","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-08-21","conditions":"Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology), Tuberculosis, Central Nervous System","enrollment":200},{"nctId":"NCT04311502","phase":"PHASE2","title":"Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-05","conditions":"HIV, Tuberculosis","enrollment":104},{"nctId":"NCT04521803","phase":"PHASE2","title":"High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis","status":"RECRUITING","sponsor":"University of Cape Town","startDate":"2022-01-10","conditions":"Tuberculous Pericarditis, HIV Status","enrollment":60},{"nctId":"NCT07129629","phase":"PHASE2","title":"Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-08-20","conditions":"Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT06423898","phase":"PHASE4","title":"Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.","status":"RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2024-10-09","conditions":"Endocarditis, Infective","enrollment":284},{"nctId":"NCT07076225","phase":"PHASE3","title":"Ultra-Short Regimen for Elderly DS-TB","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-07-25","conditions":"Pulmonary Tuberculosis","enrollment":300},{"nctId":"NCT03988933","phase":"PHASE2","title":"2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2019-09-20","conditions":"Latent Tuberculosis","enrollment":1368},{"nctId":"NCT04260477","phase":"PHASE3","title":"Novel Triple-dose Tuberculosis Retreatment Regimen","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2021-03-01","conditions":"Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis","enrollment":370},{"nctId":"NCT05221502","phase":"PHASE2","title":"Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-04-12","conditions":"Pulmonary TB","enrollment":122},{"nctId":"NCT05081401","phase":"PHASE3","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2022-05-23","conditions":"Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB","enrollment":1050},{"nctId":"NCT06191692","phase":"PHASE3","title":"1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam","status":"NOT_YET_RECRUITING","sponsor":"Freundeskreis Für Internationale Tuberkulosehilfe e.V","startDate":"2025-08-01","conditions":"Tuberculosis Infection","enrollment":350},{"nctId":"NCT06771050","phase":"PHASE4","title":"Randomised Arthroplasty Infection Worldwide Multidomain Adaptive Platform (ROADMAP) Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Newcastle, Australia","startDate":"2025-03-26","conditions":"Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Large Joint Prosthetic Joint Infections","enrollment":2500},{"nctId":"NCT05971602","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2023-07-26","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT06811792","phase":"","title":"Intrathecal Therapy for Adult Tuberculous Meningitis: Impact on Clinical Outcomes","status":"COMPLETED","sponsor":"Beijing Chest Hospital","startDate":"2010-01-01","conditions":"Tuberculous Meningitis","enrollment":837},{"nctId":"NCT05005637","phase":"PHASE2","title":"The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis with Positive IGRA","status":"COMPLETED","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2021-08-27","conditions":"Tuberculous Uveitis","enrollment":78},{"nctId":"NCT05534750","phase":"PHASE2","title":"Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-20","conditions":"Tuberculosis, Multidrug Resistant Tuberculosis","enrollment":60},{"nctId":"NCT02410772","phase":"PHASE3","title":"TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-01-25","conditions":"Tuberculosis","enrollment":2516},{"nctId":"NCT01380080","phase":"PHASE4","title":"REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-10","conditions":"HIV Infection","enrollment":851},{"nctId":"NCT04021121","phase":"PHASE2","title":"Adjunctive Linezolid for the Treatment of Tuberculous Meningitis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-05-05","conditions":"Tuberculosis, Meningeal","enrollment":40},{"nctId":"NCT04062201","phase":"PHASE3","title":"Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care","status":"COMPLETED","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2019-08-22","conditions":"Tuberculosis, Pre-XDR-TB, Extensively Drug-Resistant Tuberculosis","enrollment":402},{"nctId":"NCT03851588","phase":"PHASE2","title":"Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2019-12-19","conditions":"HIV Infections, Tuberculosis","enrollment":108},{"nctId":"NCT04121195","phase":"PHASE2, PHASE3","title":"Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2020-10-30","conditions":"HIV/AIDS, Tuberculosis","enrollment":26},{"nctId":"NCT06484530","phase":"PHASE4","title":"Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2024-03-12","conditions":"Tuberculosis (TB), Isoniazid Toxicity, Rifampicin Toxicity","enrollment":116},{"nctId":"NCT05443178","phase":"PHASE1","title":"Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2022-01-04","conditions":"Tuberculosis Infection","enrollment":16},{"nctId":"NCT05597280","phase":"PHASE3","title":"Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2023-03-22","conditions":"Leprosy","enrollment":124000},{"nctId":"NCT05169554","phase":"PHASE2","title":"Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy","status":"RECRUITING","sponsor":"Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID)","startDate":"2021-12-01","conditions":"Buruli Ulcer","enrollment":140},{"nctId":"NCT04437836","phase":"PHASE1, PHASE2","title":"Evaluation of Pharmacokinetics and Safety Tolerability of Higher Doses of Rifampic","status":"COMPLETED","sponsor":"Kilimanjaro Clinical Research Institute","startDate":"2019-07-01","conditions":"Clinical Trial","enrollment":31},{"nctId":"NCT04145258","phase":"PHASE3","title":"Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-02-07","conditions":"Tuberculous Meningitis","enrollment":768},{"nctId":"NCT06178666","phase":"NA","title":"A Controlled Human Infection Model (CHIM) With Intradermal BCG in Malawi","status":"UNKNOWN","sponsor":"Liverpool School of Tropical Medicine","startDate":"2024-03-01","conditions":"Tuberculosis","enrollment":30},{"nctId":"NCT05917340","phase":"PHASE3","title":"Intensified Short Course Regimen for TBM in Adults","status":"NOT_YET_RECRUITING","sponsor":"Indian Council of Medical Research","startDate":"2024-03","conditions":"Tuberculous Meningitis","enrollment":372},{"nctId":"NCT04721795","phase":"PHASE2, PHASE3","title":"Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)","status":"COMPLETED","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2021-01-19","conditions":"Tuberculosis, Pulmonary, Tuberculosis","enrollment":150},{"nctId":"NCT03678688","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-10-18","conditions":"Pulmonary TB","enrollment":122},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT05575518","phase":"PHASE3","title":"A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"Stellah Mpagama","startDate":"2023-08-11","conditions":"Tuberculosis, Human Immunodeficiency Virus","enrollment":414},{"nctId":"NCT02581527","phase":"PHASE3","title":"A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2017-02-01","conditions":"Pulmonary Tuberculosis","enrollment":672},{"nctId":"NCT03982277","phase":"PHASE2","title":"Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy","status":"COMPLETED","sponsor":"Makerere University","startDate":"2019-04-30","conditions":"Tuberculosis","enrollment":130},{"nctId":"NCT03832023","phase":"NA","title":"Community-based Tuberculosis Tracing and Preventive Therapy","status":"COMPLETED","sponsor":"Elizabeth Glaser Pediatric AIDS Foundation","startDate":"2019-10-14","conditions":"Tuberculosis","enrollment":1400},{"nctId":"NCT03941496","phase":"PHASE1, PHASE2","title":"Azacytidine During Anti-tuberculosis Therapy","status":"WITHDRAWN","sponsor":"Andrew Dinardo","startDate":"2022-10","conditions":"Tuberculosis, Pulmonary","enrollment":""},{"nctId":"NCT04044001","phase":"PHASE1, PHASE2","title":"BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)","status":"COMPLETED","sponsor":"Michael Hoelscher","startDate":"2019-11-15","conditions":"Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis","enrollment":77},{"nctId":"NCT02554318","phase":"NA","title":"Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2013-11","conditions":"Pulmonary Tuberculosis, Body Weight Changes, Motor Activity","enrollment":147},{"nctId":"NCT04553406","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease","status":"TERMINATED","sponsor":"Spero Therapeutics","startDate":"2020-12-03","conditions":"Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease","enrollment":2},{"nctId":"NCT05215990","phase":"PHASE1, PHASE2","title":"Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2022-01-15","conditions":"Tuberculosis, Pulmonary","enrollment":80},{"nctId":"NCT04629378","phase":"PHASE2","title":"Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2020-08-17","conditions":"Tuberculosis","enrollment":22},{"nctId":"NCT05124678","phase":"PHASE2","title":"Pharmacogenetics-guided Isoniazid Dosing in TB-HIV","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2021-12-07","conditions":"Tuberculosis","enrollment":40},{"nctId":"NCT01751568","phase":"PHASE1, PHASE2","title":"Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-11-12","conditions":"HIV Infections, Tuberculosis","enrollment":40},{"nctId":"NCT02958709","phase":"PHASE1, PHASE2","title":"Optimizing Treatment to Improve TBM Outcomes in Children","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-02-22","conditions":"Tuberculosis, Meningeal","enrollment":38},{"nctId":"NCT03927313","phase":"PHASE2","title":"Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2019-06-12","conditions":"Tuberculosis Meningitis, HIV-1-infection","enrollment":52},{"nctId":"NCT04525235","phase":"PHASE1","title":"Phenotyping of High Dose Rifampicin","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-01-07","conditions":"Tuberculosis","enrollment":25},{"nctId":"NCT04768231","phase":"PHASE2","title":"Rifampicin at High Dose for Difficult-to-Treat Tuberculosis","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2021-04-01","conditions":"Tuberculosis","enrollment":130},{"nctId":"NCT02178592","phase":"PHASE3","title":"Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-01-23","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":113},{"nctId":"NCT03561753","phase":"PHASE4","title":"Pilot Clinical Trial of PRS TB Regimen I - Phase II","status":"COMPLETED","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2017-12-01","conditions":"Pulmonary Tuberculosis TB in Sputum: (+) Microscopy","enrollment":97},{"nctId":"NCT04513379","phase":"PHASE3","title":"Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients","status":"UNKNOWN","sponsor":"Shanghai Public Health Clinical Center","startDate":"2020-11-01","conditions":"HIV Infections, Tuberculosis","enrollment":80},{"nctId":"NCT02153528","phase":"PHASE3","title":"Optimization of the TB Treatment Regimen Cascade","status":"COMPLETED","sponsor":"Damien Foundation","startDate":"2014-11","conditions":"Tuberculosis, Pulmonary","enrollment":701},{"nctId":"NCT02114684","phase":"PHASE1, PHASE2","title":"Improving Retreatment Success (IMPRESS)","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2013-11","conditions":"Recurrent Tuberculosis","enrollment":197},{"nctId":"NCT03892161","phase":"PHASE1","title":"Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers","status":"TERMINATED","sponsor":"University of Cape Town","startDate":"2018-04-12","conditions":"HIV Infections","enrollment":17},{"nctId":"NCT01392911","phase":"PHASE2","title":"Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2011-06","conditions":"Pulmonary Tuberculosis (TB)","enrollment":128},{"nctId":"NCT00130247","phase":"PHASE3","title":"Tuberculosis Treatment Shortening Trial","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-04-08","conditions":"Tuberculosis","enrollment":394},{"nctId":"NCT01516203","phase":"PHASE2","title":"Phase 2a EBA Trial of AZD5847","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-12-05","conditions":"Tuberculosis","enrollment":75},{"nctId":"NCT01601626","phase":"PHASE2","title":"Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-07-13","conditions":"HIV Infection, Tuberculosis","enrollment":71},{"nctId":"NCT03186482","phase":"PHASE1","title":"RIFT: Effect of Rifampicin on Plasma PK of FTC, TAF and Intracellular TFV-DP & FTC-TP","status":"COMPLETED","sponsor":"St. Stephens Clinical Research","startDate":"2017-06-01","conditions":"HIV","enrollment":21},{"nctId":"NCT00170209","phase":"PHASE3","title":"Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)","status":"COMPLETED","sponsor":"McGill University","startDate":"2011-08","conditions":"Latent Tuberculosis Infection","enrollment":844},{"nctId":"NCT01408914","phase":"PHASE2","title":"Trial of High-Dose Rifampin in Patients With TB","status":"COMPLETED","sponsor":"Harvard University Faculty of Medicine","startDate":"2013-09","conditions":"Tuberculosis","enrollment":180},{"nctId":"NCT01785186","phase":"PHASE2","title":"Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design","status":"COMPLETED","sponsor":"Michael Hoelscher","startDate":"2013-04","conditions":"Tuberculosis, Pulmonary","enrollment":365},{"nctId":"NCT01986543","phase":"PHASE2","title":"Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2013-12","conditions":"Tuberculosis, HIV","enrollment":105},{"nctId":"NCT02169882","phase":"PHASE2, PHASE3","title":"High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2014-12-01","conditions":"Tuberculosis, Meningeal","enrollment":60},{"nctId":"NCT00669643","phase":"PHASE4","title":"Uniform Multidrug Therapy Regimen for Leprosy Patients","status":"COMPLETED","sponsor":"University of Brasilia","startDate":"2007-02","conditions":"Leprosy","enrollment":859},{"nctId":"NCT00728507","phase":"PHASE2","title":"Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2009-11","conditions":"Tuberculosis","enrollment":121},{"nctId":"NCT01329250","phase":"PHASE4","title":"Pharmacokinetics and Safety of Moxifloxacin","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2011-05","conditions":"Tuberculosis","enrollment":9},{"nctId":"NCT00760149","phase":"PHASE2","title":"Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2010-07","conditions":"Tuberculosis","enrollment":150},{"nctId":"NCT01805258","phase":"PHASE3","title":"Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2007-06","conditions":"HIV/TB Co-infection","enrollment":135},{"nctId":"NCT01218217","phase":"PHASE2","title":"Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB","status":"COMPLETED","sponsor":"Michael Hoelscher","startDate":"2010-11","conditions":"Tuberculosis, Pulmonary","enrollment":90},{"nctId":"NCT01441206","phase":"PHASE1","title":"Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-09","conditions":"Infection","enrollment":2},{"nctId":"NCT01158755","phase":"PHASE2","title":"Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2010-10","conditions":"Meningitis, Tuberculous, Pharmacokinetics, Pharmacodynamics","enrollment":60},{"nctId":"NCT00523458","phase":"PHASE4","title":"A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV","status":"TERMINATED","sponsor":"Stanford University","startDate":"2007-07","conditions":"HIV Infections, Tuberculosis","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RIF10"],"phase":"phase_3","status":"active","brandName":"Standard dose rifampicin","genericName":"Standard dose rifampicin","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Standard dose rifampicin is used to treat conditions such as tuberculosis and pulmonary tuberculosis. It works by inhibiting bacterial DNA-directed RNA polymerase, a key enzyme in bacterial transcription.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}